- Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review
-
Miao L, Xu J, Targher G, Byrne CD, Zheng MH
- KMID: 2534339
- Clin Mol Hepatol.
- 2022 Oct;28(4):725-738.
- doi: 10.3350/cmh.2022.0015
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease with a global prevalence of about 55% in people with type 2 diabetes mellitus (T2DM). T2DM, obesity... -
- CITED
-
- Close
- SHARE
-
- Close
